Study identity card

PROLIFIC

Sweden
Share
  • Disease: Post-COVID-19
  • Study type: Randomised Clinical Trial
  • Study type descriptors: Interventional, Single centre
  • Study aim: To evaluate the efficacy of nirmatrelvir/ritonavir in providing sustained improvement in quality of life for non-hospitalized patients with post-acute COVID-19 syndrome
  • Number of participants enrolled: 219
  • Study enrolling from to
  • Study includes follow-up for 90 days

Study Data

  • Adults
  • General population
  • Elderly
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir

Other information

If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it

The data is updated up to